Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320541
Status:
COMPLETED
Last Update Posted:
2013-07-22
First Post:
2006-04-28
Brief Title:
A Trial of Paclitaxel and Bevacizumab vs Gemcitabine Paclitaxel and Bevacizumab in Advanced Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine Paclitaxel and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B9E-US-S377 | OTHER | Eli Lilly and Company | None |